Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effectiveness of the Combined WLI and Hyperthermia for GI Cancer Liver Metastasis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01963117
Recruitment Status : Terminated (Poor accrual)
First Posted : October 16, 2013
Results First Posted : March 19, 2020
Last Update Posted : March 19, 2020
Sponsor:
Information provided by (Responsible Party):
Samsung Medical Center

Brief Summary:

The standard treatment of unresectable liver metastasis in gastrointestinal tract cancer is chemotherapy, but considerable portion of the patients progressed and most of the liver is converted to metastatic tumor lesions. Significant quality of life decrement was detected in those patients, especially in patients suffered severe symptoms Several studies reported that whole liver RT (WLRT) can be used effectively to control severe symptoms from unresectable liver metastasis in gastrointestinal tract cancer patients. However, it is well known fact that the liver is a very sensitive to RT. Despite symptom palliation is obtained after 20 to 30 Gy RT but only in small subset of patients get local control. In this aspect, the combined with radiosensitizer with WLRT is considered to enhance RT effect to palliate symptom and control local tumor progression, and increase the quality of life ultimately.

It is reported that hyperthermia is considered as the most valuable radiosensitizer in cancer treatment, theoretically. Based on those studies, we start this prospective study to investigate the effect of combination treatment of WLRT and hyperthermia on quality of life in the patients with unresectable chemoresistant liver metastasis from gastrointestinal tract cancer.


Condition or disease Intervention/treatment Phase
Hyperthermia Radiation: Combined hyperthermia and radiation therapy Not Applicable

Detailed Description:

1.1 gastrointestinal tract cancer liver metastasis Most mortality of the gastrointestinal tract cancer patients is related with distant metastasis, especially liver is the main site. It has been estimated that 25% of colorectal cancer patients have hepatic metastases at diagnosis, and another 50% will have their tumor recurrence in the liver within 5 years.

Selected patients who had oligo (usually 2 to 3) or isolated liver metastases resected curatively and have yielded 5-year survival rates of 50% to 60%, showing that local therapy has the potential to cure. It is only possible in less than 25% of all patients with hepatic metastasis because of medical and/or surgical reasons, furthermore two-thirds of resected patients showed ultimately liver recurrence within 2 years.

The standard treatment of unresectable liver metastasis in gastrointestinal tract cancer is chemotherapy, but considerable portion of the patients progressed and most of the liver is converted to metastatic tumor lesions. Significant quality of life decrement was detected in those patients, especially in patients suffered severe symptoms

1.2 Radiation therapy (RT) for liver metastasis Several studies reported that whole liver RT (WLRT) can be used effectively to control severe symptoms from unresectable liver metastasis in colorectal cancer patients. However, it is well known fact that the liver is a very sensitive to RT. The radiation induced liver disease (RILD), dreadful complication without special treatment method and subset of patients could be dead, can be developed as low as 30 gray (Gy). Despite symptom palliation is obtained after 20 to 30 Gy RT but only in small subset of patients get local control. In this aspect, the combined with radiosensitizer with WLRT is considered to enhance RT effect to palliate symptom and control local tumor progression, and increase the quality of life ultimately.

1.3 Hyperthermia It is reported that hyperthermia is effective in S phase, Low oxygen partial pressure (pO2), low hydrogen ion concentration (pH), and low perfusion site which are known as radio-resistant. Because of these characteristics, it considered as the most valuable radiosensitizer in cancer treatment, theoretically. Furthermore, mild hyperthermia (41 to 41.5 ºC) can promote tumor reoxygenation.

1.4 Purpose of this study Based on those studies, we start this prospective study to investigate the effect of combination treatment of WLRT and hyperthermia on quality of life in the patients with unresectable chemoresistant liver metastasis from gastrointestinal tract cancer.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 11 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effectiveness of the Combined Whole Liver Irradiation (WLI) and Hyperthermia for Unresectable Chemoresistant Multiple Liver Metastasis From Gastrointestinal Tract Cancer: Prospective Phase II Trial
Study Start Date : October 2013
Actual Primary Completion Date : November 2014
Actual Study Completion Date : April 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Fever

Arm Intervention/treatment
Experimental: Combined hypertermia and RT
Combined hypertermia and radiothearpy
Radiation: Combined hyperthermia and radiation therapy



Primary Outcome Measures :
  1. Time to Local Tumor Progression After Combined Hyperthermia and RT [ Time Frame: Patient will be evaluated after combined hyperthermia and RT until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 19 months. ]
    Local progression will be defined as more than 20% size increase of metastatic lesions or new metastatic lesion in liver. Time to local tumor progression will be measured from the date of RT start to the date of local progression or last follow-up visit.


Secondary Outcome Measures :
  1. Objective Response Rate of Combined Hyperthermia and RT [ Time Frame: Response will be evaluated at 3 month after combined hyperthermia and RT. Modified RECIST will be used to define resopnse. ]
  2. Change in the Grade of Quality of Life at 3 Months From That Before the Combined Hyperthermia and RT [ Time Frame: Quality of life will be ssessed at baseline and 3 months after combined hyperthemica and RT, data reported 3 months after combined hyperthemica and RT with grade from 1 to 4. ]
    To measure the quality of life, European Organisation for Research and Treatment of Cancer (EORTC)- quality of life questionnaire (QLQ) 30 and Functional Assessment of Cancer Therapy-Hepatobiliary will be used. (grade 1 to 4, 1; not at all, 2; a little, 3; quite a bit, 4; very much)

  3. Local Tumor Progression Free Survival Rate After Combined Hyperthermia and RT [ Time Frame: Response will be evaluated at 3 month after combined hyperthermia and RT. Modified RECIST will be used to define resopnse. ]
    Local progression will be defined as more than 20% size increase of metastatic lesions or new metastatic lesion in liver. Local progression free survival will be measured from the date of RT start to the date of local progression or last follow-up visit.

  4. Adverse Event After Combined Hyperthermia and RT. [ Time Frame: Adverse event will be evaluated at 3 month. The common terminology criteria for adverse events (CTCAE) version 4.0 will be used. ]
    All grade III or higher toxicities (repeated measure)

  5. Overall Survival Rate After Combined Hyperthermia and RT [ Time Frame: Pathient will be evaluated at 3 month after combined hyperthermia and RT. ]
    Overall survival will be measured from the date of RT start to the date of death or last follow-up visit.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 1 Patients must have a diagnosis of pathologic proven gastrointestinal tract cancer
  • 2 Unresectable and unsuitable to other local modalities
  • 3 Not responded and/or unsuitable to chemotherapy
  • 4 Eastern Cooperative Oncology Group ECOG) performance status 0 to 3
  • 5 Assessment by colorectal tumor board (surgeon, radiation oncologist and medical oncologist participated)
  • 6 Age ≥ 20
  • 7 Agreement of study-specific informed consent
  • 8 Blood work requirements

    • Absolute neutrophil count (ANC) ≥ 1,500 /mm3, Platelet ≥ 50,000/mm3, Hgb ≥ 8 g/dl
    • Liver function test(LFT): Total bilirubin<3.0 mg/dL, International normalized ratio(INR) < 1.7, Albumin ≥ 2.8g/dL, Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT)< 6 X normal
    • Serum creatinine < 1.5 X normal, or Creatinine clearance rate (CCr) ≥ 60 mL/min
  • 9 Child-Pugh score 10 or less within 1 week before WLI
  • 10 Childbearing potential woman, consent contraception at least 6 months
  • 11 Stable breathing more than 5 minutes

Exclusion Criteria:

  • 1 Life expectancy less than 8 weeks
  • 2 Pregnant and/or breastfeeding woman
  • 3 Previous upper abdominal RT history
  • 4 Uncontrolled ascites or hepatic encephalopathy
  • 5 Unstable respiration due to pleural effusion, chronic obstructive pulmonary disease COPD) etc

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01963117


Locations
Layout table for location information
Korea, Republic of
Samsung Medical Center
Seoul, Korea, Republic of, 135-710
Sponsors and Collaborators
Samsung Medical Center
Investigators
Layout table for investigator information
Principal Investigator: Hee Chul Park, M.D., Ph.D. Samsung Medical Center
Layout table for additonal information
Responsible Party: Samsung Medical Center
ClinicalTrials.gov Identifier: NCT01963117    
Other Study ID Numbers: SMC IRB 2013-06-040
First Posted: October 16, 2013    Key Record Dates
Results First Posted: March 19, 2020
Last Update Posted: March 19, 2020
Last Verified: August 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Hyperthermia
Fever
Body Temperature Changes
Heat Stress Disorders
Wounds and Injuries